HIGHLIGHTS
- who: Siarhei A. Dabravolski et al. from the Department of Clinical Diagnostics, State Academy of Veterinary Medicine [UO VGAVM] have published the paper: Mitochondria-Mediated Cardiovascular Benefits of Sodium-Glucose Co-Transporter 2 Inhibitors, in the Journal: (JOURNAL)
- what: In this review the authors focus on the molecular mechanisms of the mitochondria-mediated beneficial effects of SGLT2 on the cardiovascular system. The authors present a comprehensive overview of the impact of SGLT2 on mitochondria and highlight the potential application of these medications to treat both T2DM and cardiovascular diseases.
- how: It is important . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.